Sunshine Biopharma (SBFM) Non-Current Debt (2014 - 2021)

Sunshine Biopharma's Non-Current Debt history runs 8 years deep, the most recent figure standing at $1.9 million for Q4 2021.

• Quarterly Non-Current Debt rose 100.21% year-over-year to $1.9 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $1.9 million (up 100.21% YoY) and the FY2021 annual result came in at $1.9 million, up 100.21% from the prior year.
• Non-Current Debt was $1.9 million for Q4 2021 at Sunshine Biopharma, down from $3.2 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $3.2 million in Q3 2021 and bottomed at $63234.0 in Q2 2020.
• A 5-year average of $1.0 million and a median of $477064.5 in 2017 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2018 — Non-Current Debt tumbled 51.41% — and 2021, when it soared 3148.59%.
• Sunshine Biopharma's Non-Current Debt stood at $596577.0 in 2017, then plunged by 51.41% to $289847.0 in 2018, then dropped by 0.01% to $289825.0 in 2019, then surged by 227.44% to $949006.0 in 2020, then jumped by 100.21% to $1.9 million in 2021.
• Business Quant data shows SBFM's Non-Current Debt at $1.9 million in Q4 2021, $3.2 million in Q3 2021, and $2.1 million in Q2 2021.